Thus, our studies provide evidence that a potent and clinically safe AR inhibitor, fidarestat, could be a novel adjuvant drug to increase the sensitivity of colon cancer cells to DOX and also to prevent cardiotoxicity associated with the effective and relatively inexpensive synthetic anthracycline drugs. The gene discussed is AR; the disease is colonic neoplasm.